CBG Gains Attention in Veterinary Care

Cannabigerol (CBG) is gaining attention in veterinary care. This non-intoxicating cannabis compound shows therapeutic promise for animals.

Early research suggests its anti-inflammatory effects may surpass CBD's. It suits topical use for skin irritation. This offers a new option for conditions like atopic dermatitis. The compound may also aid patients with inflammatory bowel disease and metabolic syndrome.

How CBG Compares to Other Cannabinoids

To understand CBG, know its relationship to other cannabis compounds. Veterinarians avoid THC due to toxicity. CBD modulates THC's effects and acts on receptors linked to anxiety and inflammation.

CBG sits between THC and CBD pharmacologically. It has lower receptor affinity than THC but shares similarities with CBD at ion channels. A key difference is CBG's action at the α-2 adrenoceptor. This mechanism is not documented for CBD or THC.

Potential Therapeutic Applications for Pets

The report outlines several promising areas for animal health.

For skin problems, topical CBG helped animal models of atopic dermatitis. It reduces inflammation. It strengthens the skin's barrier. The compound also has antioxidant, anti-acne, and anti-aging activity. In human studies, a CBG serum improved skin hydration and reduced redness versus a placebo.

In inflammatory bowel disease (IBD), CBG may outperform CBD. It directly impacts gut inflammation in cases like Crohn's disease. It engages intestinal cannabinoid receptors. Studies in mice found a high-CBG hemp extract reduced colitis and normalized inflammatory pathways.

Fighting Infection and Metabolic Issues

CBD and CBG are researched for killing drug-resistant bacteria. CBG damages cell walls of gram-positive bacteria. It disrupts biofilms. It increases bacterial membrane permeability.

CBG was potent against antibiotic-resistant Staphylococcus aureus. In mouse models of systemic infection, CBG reduced bacterial counts as effectively as vancomycin.

Studies on CBG for metabolic syndrome are growing. The report references overlapping benefits with other receptor agonists. It does not provide specific comparative data for pets.

Safety and Current Outlook

A survey of human patients using CBG-predominant cannabis reported greater efficacy over conventional drugs. Adverse events were manageable. Withdrawal symptoms were negligible.

Much remains to be tested in veterinary patients. Its unique receptor profile and early research point to an expanding role. This includes skin treatments and fighting stubborn infections.